Showing 1 - 1 results of 1 for search '(((("peter decrease") OR ((("year decrease") OR ("smear decrease"))))) OR ("mean decrease"))*', query time: 0.09s Refine Results
  1. 1

    The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target? by Al-Shamasi, Al-Anood

    Published 2020
    “…In this trial, treatment with EMPA over 2.6 years decreased cardiovascular vascular events (14% reduction). …”
    Get full text
    Get full text